| Chronic Obstructive Airway Disease
Tudorza Pressair vs Yupelri
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Tudorza Pressair vs Yupelri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYupelri has a higher rate of injection site reactions vs Tudorza Pressair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yupelri but not Tudorza Pressair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tudorza Pressair
Yupelri
At A Glance
Oral inhalation
Twice daily
Anticholinergic
Inhaled (nebulizer)
Once daily
Long-acting muscarinic antagonist
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease One oral inhalation of 400 mcg twice daily (morning and evening approximately 12 hours apart).
Chronic Obstructive Airway Disease 175 mcg (one unit-dose vial) inhaled once daily via standard jet nebulizer with mouthpiece.
Contraindications
- Severe hypersensitivity to milk proteins
- Hypersensitivity to aclidinium bromide or any excipient
- Hypersensitivity to revefenacin or any component of this product
Adverse Reactions
Most common (>=1%) Headache, nasopharyngitis, cough, diarrhea, sinusitis, rhinitis, toothache, fall, vomiting
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Anaphylaxis, angioedema, urticaria, rash, bronchospasm, itching, nausea, dysphonia, blurred vision, urinary retention, tachycardia, stomatitis
Most common (>=2%) Cough, nasopharyngitis, upper respiratory tract infection, headache, back pain
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Dry mouth
Pharmacology
Aclidinium bromide is a long-acting antimuscarinic (anticholinergic) agent that inhibits M3 muscarinic receptors on airway smooth muscle, causing bronchodilation; the bronchodilatory effect is predominantly site-specific following inhalation.
Revefenacin is a long-acting muscarinic antagonist (anticholinergic) that competitively and reversibly inhibits M3 receptors at airway smooth muscle, leading to bronchodilation predominantly through a site-specific effect following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tudorza Pressair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Yupelri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (4/12)
UnitedHealthcare
Tudorza Pressair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Yupelri
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Tudorza Pressair
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Yupelri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tudorza Pressair.
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Tudorza PressairView full Tudorza Pressair profile
YupelriView full Yupelri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.